CDK12 and neoplasm: In TALAPRO-2, HRR status was assessed in tumor tissue, and a subsequent protocol amendment permitted prospective ctDNA testing (FoundationOne CDx); the genes analyzed were ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C [62].